logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

“Bringing clinical trials closer to the patient’s home is a challenge in which the public and private sectors must go hand in hand”

This measure allows for greater participation and the inclusion of a more diverse population, which improves the scientific quality of the studies, as highlighted by Farmaindustria’s Associate Director of Clinical and Translational Research, Amelia Martín Uranga at an IESE Healthcare conference in Barcelona

Source: farmaindustria.es

The healthcare crisis triggered by the Covid-19 pandemic highlighted the importance and commitment of the pharmaceutical industry to the research and development of new medicines. In fact, in the field of clinical trials, it meant an acceleration in the digital transformation of R&D&I for new medicines, taking advantage of available technology and healthcare data to bring clinical trials closer to the patient’s home in a context of increasing decentralisation of clinical research.

“Bringing clinical trials closer to the patient’s home allows for better recruitment and inclusion of a more diverse population, resulting in better scientific quality of study data. In addition, this type of study not only saves travel for patients and monitors, but also provides greater flexibility for all those involved in the research process, as well as better follow-up of study participants”. This was reflected by Farmaindustria’s Associate Director of Clinical and Translational Research, Amelia Martín Uranga, at the conference The home is the new hospital, recently organised by IESE Healthcare in Barcelona, which focused on key new trends in technology and how to reshape the healthcare of the future.

Several of these measures, he stressed, were already adopted during the Covid pandemic and now regulators are working to ensure that they can be sustained over time, in line with the recommendations document published under the ACT EU initiative, a project led by the European Commission, the European Medicines Agency and the Network of Heads of Medicines Agencies. “This initiative is an important first step towards clarifying the use of decentralised clinical trials in the European Union by the European medicines regulatory network. The document addresses the roles and responsibilities of both sponsor and investigator in terms of electronic informed consent (eConsent), delivery of investigational medicines to the patient’s home, remote monitoring and other elements that aim to bring the trial closer to the patient’s home, while ensuring the rights and welfare of patients, as well as the integrity and reliability of the data collected,” he said.

Farmaindustria is also working in this area, he said, which has an ad hoc group that has been working on different decentralised elements in order to advance the development of a national guide on the application of decentralised elements in clinical trials with medicines. This group is also working with an autonomous community that is interested in establishing standardised working procedures for networked clinical trials by its centres, said the Farmaindustria spokeswoman.

European Health Data Space

This digital transformation of clinical trials is taking place at a time when the Proposal for a regulation on the European Health Data Space is being discussed. The pharmaceutical industry sees this regulation as a great opportunity to improve healthcare for European citizens by ensuring the continuity of treatments and the widespread availability of their clinical information in secure environments. “To this end, it is essential to enhance public-private collaboration. Bringing clinical trials closer to the patient’s home is a challenge in which the public and private sectors must work hand in hand. As the pandemic has already shown, cooperation between industry, research centres and healthcare professionals is the best formula for accelerating and promoting the arrival of new innovative medicines to society,” he concluded.

Related entries

2 October, 2023

Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research


Leer más
26 September, 2023

More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society


Leer más
19 September, 2023

The pharmaceutical industry’s plan to expand clinical trials in primary care


Leer más

Recent Posts

  • Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research
  • More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society
  • The pharmaceutical industry’s plan to expand clinical trials in primary care
  • Health commitment to the pharmaceutical industry’s Strategic Plan to avoid losing 8,000 million euros
  • Improving patient access to innovative medicines and boosting R&D and manufacturing in Spain are the main priorities of the pharmaceutical industry

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

DELEGACIÓN MADRID

+34 674 575 115
28010 Madrid

Enlaces de interés

  • Aviso Legal
  • Política de privacidad
  • Política de cookies
  • Contacto

© 2023 Distefar del Sur SL. Todos los derechos reservados. agencianodo.com

  • No translations available for this page
  • Contact
  • Private Zone
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.